Filing Flows

Filing Flows › Companies › Travere Therapeutics › Cash flow

Travere Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$98.2M in Q3 2026 · $177M over twelve months

Operating cash flow$98.2M
Free cash flow+$98.2M
Cash conversion cycle1018 days

Analysis

In Q3 2026, Travere Therapeutics generated $98.2M of operating cash flow. That is $84.0M more than in Q3 2025 ($14.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was $177M; the largest uses were other investing ($409M); besides operations, cash came from other financing ($159M), shares issued ($86.4M); the cash balance rose by $12.6M.

Operating cash flow was $98.2M against net income of −$52.3M. The largest differences: receivables −$41.9M, stock-based pay +$23.4M, payables +$13.7M.

Its cash conversion cycle was 1018 days (receivables 39 + inventory 1345 − payables 365).

Free cash flow

Travere Therapeutics: free cash flow by quarterTravere Therapeutics: free cash flow by quarter−$35.7MQ4 2024−$42.2MQ1 2025$5.0MQ2 2025$14.2MQ3 2025$60.7MQ4 2025−$40.4MQ1 2026$58.1MQ2 2026$98.2MQ3 2026
Operating cash flow less capital spending.
Travere Therapeutics: operating cash flow against capital spendingTravere Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$35.7M$0Q4 2024−$42.2M$0Q1 2025$5.0M$0Q2 2025$14.3M$140KQ3 2025$60.7M$0Q4 2025−$40.4M$0Q1 2026$58.1M$0Q2 2026$98.2M$0Q3 2026
Latest (Q3 2026): Operating cash flow $98.2M, Capital spending $0.

Capital allocation, year by year

Travere Therapeutics: where the cash came from (up) and went (down), by fiscal yearTravere Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$14.8MFY2021: Shares issued $202MFY2021: Capital spending −$5.1M$202MFY2021FY2022: Operating cash flow −$186MFY2022: Net borrowing $105MFY2022: Shares issued $4.6MFY2022: Capital spending −$191K$110MFY2022FY2023: Operating cash flow −$280MFY2023: Shares issued $194MFY2023: Capital spending −$668K$194MFY2023FY2024: Operating cash flow −$237MFY2024: Shares issued $139M$139MFY2024FY2025: Operating cash flow $37.8MFY2025: Net borrowing −$68.9MFY2025: Shares issued $34.7M$72.5MFY2025
Over these 5 years operating cash flow totalled −$681M; the largest uses were operating cash flow ($719M) and net borrowing ($68.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$303M
Debtnone
Net cash$303M

Travere Therapeutics funds itself: free cash flow was $177M over the last twelve months, with $303M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Travere Therapeutics: sources (+) and uses (−) of cash, Q3 2026Travere Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing−$120MOperating cash flow$98.2MShares issued$27.9MCash drawn (+) / kept (−)−$5.8MOther financing−$603KExchange rates−$59K
Travere Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Travere Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$409MOperating cash flow$177MOther financing$159MShares issued$86.4MCash drawn (+) / kept (−)−$12.6MExchange rates−$460K

From profit to cash

Travere Therapeutics: net income to operating cash flow, Q3 2026Travere Therapeutics: net income to operating cash flow, Q3 2026Net income−$52.3MDepreciation & amortization$5.2MStock-based pay$23.4MOther non-cash−$1.0MReceivables−$41.9MInventory−$2.6MPayables$13.7MPrepaid and other assets−$3.0MOther liabilities−$6.9MOperating cash flow$98.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20263913453651018
Q2 20264516144271232
Q1 2026591689870878
Q4 2025581328775611
Q3 202534218310841133
Q2 202529226410321261
Q1 202534768374428
Q4 2024321527842717

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$98.2M——$27.9M−$5.8M$98.2M
Q2 2026$58.1M——$27.8M−$39.4M$58.1M
Q1 2026−$40.4M——$4.7M$14.7M−$40.4M
Q4 2025$60.7M——$25.9M$17.9M$60.7M
Q3 2025$14.3M−$140K−$68.9M$4.1M−$35.8M$14.2M
Q2 2025$5.0M——$463K−$13.3M$5.0M
Q1 2025−$42.2M——$4.2M−$3.4M−$42.2M
Q4 2024−$35.7M——$3.9M−$22.1M−$35.7M

Travere Therapeutics: income statement and cash flow

Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%. The chart follows the revenue to costs, profit and cash.

Travere Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.